MEI Pharma MEIP Stock
MEI Pharma Price Chart
MEI Pharma MEIP Financial and Trading Overview
MEI Pharma stock price | 2 USD |
Previous Close | 7.25 USD |
Open | 7.3 USD |
Bid | 0 USD x 1300 |
Ask | 0 USD x 1100 |
Day's Range | 7.12 - 7.38 USD |
52 Week Range | 4 - 13.4 USD |
Volume | 31.95K USD |
Avg. Volume | 67.84K USD |
Market Cap | 48.97M USD |
Beta (5Y Monthly) | 0.969366 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -5.73 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 28 USD |
MEIP Valuation Measures
Enterprise Value | -50678288 USD |
Trailing P/E | N/A |
Forward P/E | -1.0761347 |
PEG Ratio (5 yr expected) | 11.7 |
Price/Sales (ttm) | 0.8332401 |
Price/Book (mrq) | 1.4255236 |
Enterprise Value/Revenue | -0.862 |
Enterprise Value/EBITDA | 1.221 |
Trading Information
MEI Pharma Stock Price History
Beta (5Y Monthly) | 0.969366 |
52-Week Change | -33.18% |
S&P500 52-Week Change | 20.43% |
52 Week High | 13.4 USD |
52 Week Low | 4 USD |
50-Day Moving Average | 6.35 USD |
200-Day Moving Average | 6.5 USD |
MEIP Share Statistics
Avg. Volume (3 month) | 67.84K USD |
Avg. Daily Volume (10-Days) | 29.9K USD |
Shares Outstanding | 6.66M |
Float | 5.6M |
Short Ratio | 2.98 |
% Held by Insiders | 0.54% |
% Held by Institutions | 39.34% |
Shares Short | 304.41K |
Short % of Float | 4.59% |
Short % of Shares Outstanding | 4.57% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | June 30, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | June 30, 2023 |
Profitability
Profit Margin | -64.43% |
Operating Margin (ttm) | -71.25% |
Gross Margin | 100.00% |
EBITDA Margin | -70.62% |
Management Effectiveness
Return on Assets (ttm) | -15.92% |
Return on Equity (ttm) | -74.14% |
Income Statement
Revenue (ttm) | 58.77M USD |
Revenue Per Share (ttm) | 8.82 USD |
Quarterly Revenue Growth (yoy) | -39.20% |
Gross Profit (ttm) | 40.7M USD |
EBITDA | -41507000 USD |
Net Income Avi to Common (ttm) | -37872000 USD |
Diluted EPS (ttm) | -5.79 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 112.04M USD |
Total Cash Per Share (mrq) | 16.82 USD |
Total Debt (mrq) | 13.05M USD |
Total Debt/Equity (mrq) | 37.99 USD |
Current Ratio (mrq) | 5.101 |
Book Value Per Share (mrq) | 5.156 |
Cash Flow Statement
Operating Cash Flow (ttm) | -56686000 USD |
Levered Free Cash Flow (ttm) | -17083000 USD |
Profile of MEI Pharma
Country | United States |
State | CA |
City | San Diego |
Address | 11455 El Camino Real |
ZIP | 92130 |
Phone | 858 369 7100 |
Website | https://www.meipharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 102 |
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Q&A For MEI Pharma Stock
What is a current MEIP stock price?
MEI Pharma MEIP stock price today per share is 2 USD.
How to purchase MEI Pharma stock?
You can buy MEIP shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for MEI Pharma?
The stock symbol or ticker of MEI Pharma is MEIP.
Which industry does the MEI Pharma company belong to?
The MEI Pharma industry is Biotechnology.
How many shares does MEI Pharma have in circulation?
The max supply of MEI Pharma shares is 6.66M.
What is MEI Pharma Price to Earnings Ratio (PE Ratio)?
MEI Pharma PE Ratio is now.
What was MEI Pharma earnings per share over the trailing 12 months (TTM)?
MEI Pharma EPS is -5.73 USD over the trailing 12 months.
Which sector does the MEI Pharma company belong to?
The MEI Pharma sector is Healthcare.
MEI Pharma MEIP included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15587.79 USD — |
-5.82
|
9.14B USD — | 15575.68 USD — | 16128.16 USD — | — - | 9.14B USD — |
NASDAQ Capital Market Composite RCMP | 92.16 USD — |
-4.45
|
— — | 89.57 USD — | 93.85 USD — | — - | — — |
NASDAQ HealthCare IXHC | 869.8 USD — |
-5.51
|
— — | 868.74 USD — | 900.72 USD — | — - | — — |
NASDAQ Composite Total Return I XCMP | 19079.55 USD — |
-5.82
|
— — | 19064.73 USD — | 19740.96 USD — | — - | — — |
- {{ link.label }} {{link}}